Dynamics of soluble and cellular inflammatory markers in nasal lavage obtained from Cystic Fibrosis patients during intravenous antibiotic treatment

Table 1 Inflammation markers in controls and CF patients before and during AB treatment

Analyte	DL	Detection frequency (%)				Inflammatory marker concentration
		Detection frequency (%)				Median			Range			P
		Controls	CF prior therapy	CF during therapy	P	Controls	CF before therapy	CF during therapy	Controls	CF before therapy	CF during therapy	P
MMP9 (ng/mL)	0.095	n.m.	100.0	100.0	---	n.m.	11.4	5.5	n.m.	2.02-122.2	1.8-25.2	0.0523^‡
MPO (ng/mL)	0.2	71.2	100.0	100.0	0.0008^◊†	33.4	215.3	171.9	0.1-182.7	54.36-531.1	21.4-533.4	0.0008^◊†
MPO (ng/mL)	0.2	71.2	100.0	100.0	0.0008^◊†	33.4	215.3	171.9	0.1-182.7	54.36-531.1	21.4-533.4	0.7404^‡
IL-8 (pg/mL)	0.5	61.5	94.1	88.2	0.0008^◊†	92.6	1145.3	756.1	0.4-11514.8	0.4-1976.7	0.4-2265.6	0.0008^◊†
IL-8 (pg/mL)	0.5	61.5	94.1	88.2	0.7728^‡	92.6	1145.3	756.1	0.4-11514.8	0.4-1976.7	0.4-2265.6	0.4488^‡
IL-6 (pg/mL)	1.2	1.9	60.0	46.7	0.0008^◊†	0.1	45.1	1.1	1.1-80.2	1.1-104.9	1.1-40.2	0.0008^◊†
IL-6 (pg/mL)	1.2	1.9	60.0	46.7	0.4237^‡	0.1	45.1	1.1	1.1-80.2	1.1-104.9	1.1-40.2	0.0059^‡
IL-1β (pg/mL)	4.2	3.8	73.3	60.0	0.0008^◊†	4.1	174.5	130.6	4.1-152.8	4.1-779.3	4.1-1052.8	0.0008^◊†
IL-1β (pg/mL)	4.2	3.8	73.3	60.0	0.3428^‡	4.1	174.5	130.6	4.1-152.8	4.1-779.3	4.1-1052.8	0.8311^‡
TNF (pg/mL)	3.2	15.4	60.0	66.7	0.0008^◊†	3.1	55.4	55.4	3.1-46.6	3.1-1036.0	3.1-242.5	0.6416^◊†
TNF (pg/mL)	3.2	15.4	60.0	66.7	0.7656^‡	3.1	55.4	55.4	3.1-46.6	3.1-1036.0	3.1-242.5	0.5693^‡
RANTES (pg/mL)	25.0	n.m.	73.3	53.3	0.1294^‡	n.m.	287.7	25.0	n.m.	25.0-1612.0	25.0-646.4	0.0942^‡
NE (ng/mL)	0.16	n.m.	100.0	100.0	---	n.m.	0.9	0.8	n.m.	0.27-5.0	0.3-11.4	0.9382^‡

^◊ P-value between controls and CF before therapy (after Bonferroni adjustment), ^† P-value between controls and CF during therapy (after Bonferroni adjustment), ^‡ P-value between CF before and during therapy. DL = Detection Limit, n.m. = not measured.

ISSN: 1471-2466